Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
LENZ Completes Merger with Graphite Bio and Updates On Progress
Details : The net proceeds will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free, single-use, once-daily eye drops for treating presbyopia.
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 21, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : LENZ Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Details : The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 15, 2023
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : LENZ Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Details : The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyo...
Product Name : LNZ101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 15, 2023
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Kamau Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Kamau will focus on the clinical development of lead program Nula-Cel (nulabeglogene autogedtemcel), which is being evaluated in Phase I/II clinical trial studies for the treatment of sickle cell disease.
Product Name : GPH101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Kamau Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GPH101 (nula-cel), is an investigational next-generation gene editing autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).
Product Name : GPH101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nula-cel, formerly known as GPH101, is an investigational next-generation gene-editing autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).
Product Name : GPH101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GPH102
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GPH102 is designed to replace the mutated beta-globin gene with a functional gene and restore adult hemoglobin (HbA) expression to levels similar to individuals who do not have the disease.
Product Name : GPH102
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : GPH102
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The preclinical data support CEDAR clinical trial, a Phase 1/2 study evaluating the safety, pharmacodynamics, engraftment success, gene correction rates and total hemoglobin, as well as other clinical and exploratory endpoints of GPH101 in patients with ...
Product Name : GPH101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease
Details : First patient expected to be treated by GPH101 in first half of 2022, GPH101 an investigational next-generation gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease.
Product Name : GPH101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GPH101 harnesses the power of CRISPR and natural DNA repair mechanisms to precisely insert the correct DNA sequence, with the aim of directly correcting the disease-causing sickle mutation and leading to the production of normal red blood cells.
Product Name : GPH101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : Nulabeglogene Autogedtemcel
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable